COVID-19 in patients with gout on colchicine
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Robinson PC, Yazdany J (2020) The COVID-19 global rheumatology alliance: collecting data in a pandemic. Nat Rev Rheumatol 16:293–294. https://doi.org/10.1038/s41584-020-0418-0
Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y et al (2020) Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 395:e52. https://doi.org/10.1016/S0140-6736(20)30558-4
Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R et al (2020) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79:760–770. https://doi.org/10.1136/annrheumdis-2019-216653
Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R et al (2020) COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 38:175–180
Pelechas E, Drossou V, Voulgari PV, Drosos AA (2020) Anti-rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2): what is the evidence? Mediterr J Rheumatol 31:259–267. https://doi.org/10.31138/mjr.31.3.259
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 79:859–866. https://doi.org/10.1136/annrheumdis-2020-217871
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667–668. https://doi.org/10.1136/annrheumdis-2020-217424
Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V et al (2020) COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol 72:1981–1989. https://doi.org/10.1002/art.41456
Migkos MP, Kaltsonoudis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A (2021) Use of conventional synthetic and biologic disease- modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int Mar 3:1–7. https://doi.org/10.1007/s00296-021-04818-2
Hyrich KL, Machado PM (2021) Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol 17:71–72. https://doi.org/10.1038/s41584-020-00562-2
Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-219498
US National Library of Medicine. Clinical Trials. Colchicine coronavirus SARS-CoV-2 Trial (COLCORONA) (COVID-19). NCT04322682. https://clinicaltrials.gov/ct2/show/NCT04322682. Accessed Mar 2021
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P et al (2020) Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open 3:e2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136
Cure MC, Kucuk A, Cure E (2020) Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol 39:2101–2102. https://doi.org/10.1007/s10067-020-05144-x
Sobodnick A, Shah B, Pillinger MH, Krasnokutsky S (2015) Colchicine: old and new. Am J Med 128:461–470. https://doi.org/10.1016/j.amjmed.2014.12.010
Leung YY, Hui LLY, Kraus VB (2015) Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 45:341–350. https://doi.org/10.1016/j.semarthrit.2015.06.013
Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH (2018) Update on colchicine, 2017. Rheumatology (Oxford) 57:i4–i11. https://doi.org/10.1093/rheumatology/kex453
Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K et al (2013) Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 62:1817–1825. https://doi.org/10.1016/j.jacc.2013.08.726
Vrachatis DA, Giannopoulos GV, Giotaki SG et al (2020) Impact of colchicine on mortality in patients with COVID-19: a meta- analysis. Hellenic J Cardiol. https://doi.org/10.1016/j.hjc.2020.11.012
Deftereos S, Giannopoulos G, Vrachatis DA, Siasos G, Giotaki SG, Cleman M et al (2020) Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? Eur Heart J Cardiovasc Pharmacother 6:255. https://doi.org/10.1093/ehjcvp/pvaa033
Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM et al (2021) Beneficial effects of colchicine for moderate to severe COVID-19: a randomized, double-blinded, placebo-controlled clinical trial. RMD Open 7:e001455. https://doi.org/10.1136/rmdopen-2020-001455
Cookson BT, Brennan MA (2001) Pro-inflammatory programmed cell death. Trends Microbiol 9:113–114. https://doi.org/10.1016/s0966-842x(00)01936-3
Chen IY, Moriyama M, Chang MF, Ichinohe T (2019) Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Fron Microbiol 10:50. https://doi.org/10.3389/fmicb.2019.00050
Reyes AZ, Hu KA, Teperman J, Muskardin TLW, Tardif JC, Shah B, Pillinger MH (2021) Ann Rheum Dis 80:550–557. https://doi.org/10.1136/annrheumdis-2020-219174
Kobak S (2021) COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Ann Rheum Dis 80:e39